Related Experiment Video

Updated: May 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

A novel treatment for glioblastoma: integrin inhibition

Marc C Chamberlain1, Timothy Cloughsey, David A Reardon

  • 1Department of Neurology & Neurological Surgery, Division of Neuro-Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, MS G-4940, Seattle, WA 98109-1023, USA. chambemc@uw.edu

Expert Review of Neurotherapeutics
|March 28, 2012
PubMed

Insights

New therapies targeting integrins show promise for treating glioblastoma (GBM), the most common malignant brain tumor. Anti-integrin strategies offer potential anti-angiogenesis, anti-invasion, and anti-tumor effects for GBM patients.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer research

Background:

  • Glioblastoma (GBM) is the most common and fatal primary brain tumor.
  • Current treatments offer limited efficacy, highlighting the need for novel therapeutic strategies.
  • Integrins play crucial roles in GBM cell signaling, proliferation, motility, and angiogenesis.

Purpose of the Study:

  • To review the epidemiology and molecular biology of GBM.
  • To focus on the role of integrins in GBM.
  • To summarize the therapeutic potential of anti-integrin strategies and ongoing clinical trials in GBM.

Main Methods:

  • Literature review of GBM epidemiology and molecular pathways.
  • Detailed analysis of integrin function in GBM.
  • Summary of completed and future clinical trials involving integrin inhibitors for GBM.

Main Results:

  • Integrins are key mediators of GBM-relevant pathways including proliferation, motility, survival, and angiogenesis.
  • Anti-integrin strategies demonstrate potential for anti-angiogenesis, anti-invasion, and anti-tumor effects.
  • Clinical trials of integrin inhibitors are most advanced in GBM, with ongoing studies for newly diagnosed and recurrent disease.

Conclusions:

  • Integrin inhibitors represent a promising therapeutic avenue for glioblastoma.
  • Targeting integrins offers a multi-faceted approach to combatting GBM.
  • Further clinical investigation of integrin-targeted therapies is warranted for GBM treatment.

More Related Videos

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Related Concept Videos

Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.